Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV20-0251 in Advanced/Refractory Solid Tumors
NCT07106827Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GV20-0251 in solid tumor, sponsored by West China Hospital of Sichuan University. Primary endpoint: Evaluate GV20-0251 safety at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
GV20-0251
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07106827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106827.